Ionis Pharmaceuticals Inc
$ 74.48
-0.87%
05 Jun - close price
- Market Cap 12,308,756,000 USD
- Current Price $ 74.48
- High / Low $ 75.96 / 73.81
- Stock P/E N/A
- Book Value 2.96
- EPS -2.01
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.68 %
- 52 Week High 86.74
- 52 Week Low 34.78
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Analyst Target Price
$100.92
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-21 | 2023-11-02 | 2023-08-09 |
| Reported EPS | -0.3 | -1.1481 | -0.61 | 0.85 | -0.93 | -0.4304 | -0.95 | -0.24 | -0.77 | -0.06 | -0.85 | -0.41 |
| Estimated EPS | -0.77 | -1.33 | -1.05 | 0.16 | -1.13 | -0.8444 | -1.16 | -0.76 | -0.83 | -0.83 | -0.89 | -0.7 |
| Surprise | 0.47 | 0.1819 | 0.44 | 0.69 | 0.2 | 0.414 | 0.21 | 0.52 | 0.06 | 0.77 | 0.04 | 0.29 |
| Surprise Percentage | 61.039% | 13.6767% | 41.9048% | 431.25% | 17.6991% | 49.0289% | 18.1034% | 68.4211% | 7.2289% | 92.7711% | 4.4944% | 41.4286% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.09 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.186 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IONS
2026-06-06 22:39:37
This article focuses on the price to book ratio of Ionis Pharmaceuticals, Inc. (XETR:ISI), providing a direct link to financial information for the company on TradingView. It highlights where to find specific financial data and market-related information for investors.
2026-06-04 16:09:09
Ionis Pharmaceuticals announced new data from its Phase III CORE and CORE2 studies on olezarsen, a drug designed to treat severe hypertriglyceridemia (sHTG). The drug demonstrated a 72.2% reduction in triglyceride levels and an 85% relative risk reduction for acute pancreatitis. Despite promising clinical results, GuruFocus indicates that Ionis Pharmaceuticals (IONS) is currently 38.1% overvalued, with a moderate GF Score™ of 69/100, and has seen significant insider selling.
2026-06-04 10:40:04
Ionis Pharmaceuticals, Inc. will present new data analyses from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG) at upcoming medical conferences. These presentations will detail how olezarsen impacts patients with different clinical backgrounds, building upon previous results showing significant reductions in fasting triglycerides and acute pancreatitis events. The U.S. FDA is currently reviewing olezarsen's marketing application for sHTG, with a target action date of June 30, 2026.
2026-06-04 10:39:23
Ionis Pharmaceuticals will present new data analyses from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG) at three upcoming medical conferences. These presentations will expand on previous results demonstrating olezarsen's significant reduction in fasting triglycerides and acute pancreatitis events with a favorable safety profile. The marketing application for olezarsen for sHTG is currently under Priority Review by the U.S. Food and Drug Administration, with a target action date of June 30, 2026.
2026-06-04 10:39:23
Ionis Pharmaceuticals (NASDAQ: IONS) announced it will present new data analyses from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG) at upcoming medical conferences. These presentations will provide further insight into how olezarsen impacts patients, with previous results showing significant reductions in fasting triglycerides and acute pancreatitis events. The marketing application for olezarsen is currently under Priority Review with the U.S. FDA, with a target action date of June 30, 2026.
2026-06-04 02:40:04
Ionis Pharmaceuticals' fair value has increased to $100.92 due to higher assumed revenue growth, improved profit margins, and a lower future P/E multiple, backed by positive analyst reports and new Buy initiations. While bullish analysts highlight the potential of Tryngloza and upcoming Phase 3 readouts as key drivers for significant sales opportunities, bearish views caution about valuation risks if product launches or clinical readouts fall short of expectations, pointing to the mixed views on future pipeline influence on current P/E multiples. The company faces both opportunities for substantial market share gains through expanding indications and strategic partnerships, as well as risks related to pricing pressures, regulatory hurdles, and reliance on late-stage assets.
